Business Context and Reporting Period
This Form 8-K was filed by PharmAthene, Inc. (not Altimmune, Inc.) on September 12, 2014, reporting events occurring on September 9, 2014. The filing details a material definitive agreement entered into with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. The primary financial data relates to the new government contract:
- Initial Funding: Approximately $5.2 million expected over the base period (includes cost reimbursement and fixed fees).
- Total Potential Value: Up to approximately $28.1 million if all milestones are met and options exercised.
- Option Value: Approximately $22.9 million available through up to eight discretionary options.
Material Changes
The material change is the execution of a development agreement for a next-generation anthrax vaccine based on PharmAthene's proprietary rPA technology. The agreement is incrementally funded and effective September 10, 2014. If all options are exercised, the contract term could extend until January 2020.
Outlook, Risks, and Contingencies
Outlook: The agreement supports process development, stability testing, preclinical studies, and manufacturing activities. Funding is contingent upon the achievement of specific milestone events and the exercise of options by NIAID at its sole discretion.
Risks and Contingencies: The total contract value is not guaranteed; it depends entirely on NIAID's discretion to exercise options and the company's ability to meet development milestones. The filing includes a press release as Exhibit 99.1, which is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the distinction between the registrant (PharmAthene, Inc.) and the company name provided in the request metadata (Altimmune, Inc.).
- Confirm the specific milestone events required to trigger the fixed fee components of the $5.2 million initial funding.
- Review the attached press release (Exhibit 99.1) for additional details on the rPA anthrax vaccine technology platform.
- Assess the probability of NIAID exercising the eight optional periods totaling $22.9 million based on historical government contract performance.